Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling.
The diagnostic of Amyotrophic lateral sclerosis (ALS) remains based on clinical and neurophysiological observations. The actual delay between the onset of the symptoms and diagnosis is about 1 year, preventing early inclusion of patients into clinical trials and early care of the disease. Therefore,...
Guardado en:
Autores principales: | Laurence Conraux, Catherine Pech, Halim Guerraoui, Denis Loyaux, Pascual Ferrara, Jean-Claude Guillemot, Vincent Meininger, Pierre-François Pradat, François Salachas, Gaëlle Bruneteau, Nadine Le Forestier, Lucette Lacomblez |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9a2d498492274d5393a990430a9c586a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Platelet serotonin level predicts survival in amyotrophic lateral sclerosis.
por: Luc Dupuis, et al.
Publicado: (2010) -
Detection of Staphylococcus aureus delta-toxin production by whole-cell MALDI-TOF mass spectrometry.
por: Julie Gagnaire, et al.
Publicado: (2012) -
NEW OPPORTUNITIES TO IDENTIFY AND TYPE STAPHYLOCOCCUS spp. BY USING MALDI-TOF MASS SPECTROMETRY
por: A. S. Stepanov, et al.
Publicado: (2018) -
DIFFERENTIATION OF KLEBSIELLA spp. STRAINS FOR SENSITIVITY TO ANTIBIOTICS USING MASS SPECTROMETRY ANALYSIS MALDI-TOF
por: I. V. Likhachev, et al.
Publicado: (2018) -
MALDI-TOF MASS SPECTROMETRY ANALYSIS FOR DETECTION OF THE RIBOSOMAL MARKERS TO IDENTIFY OF YERSINIA KRISTENSENII STRAINS
por: E. V. Zueva, et al.
Publicado: (2018)